ASLAN Pharmaceuticals Limited (ASLN)

Market Cap	44.63M
Revenue (ttm)	n/a
Net Income (ttm)	-51.38M
Shares Out	16.35M
EPS (ttm)	-3.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,568
Open	2.73
Previous Close	2.64
Day's Range	2.73 - 2.73
52-Week Range	1.71 - 4.95
Beta	1.86
Analysts	Buy
Price Target	19.13 (+600.73%)
Earnings Date	Apr 26, 2023

About ASLN

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop im...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2018
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: ASLN

Analyst Forecast

According to 8 analysts, the average rating for ASLN stock is "Buy." The 12-month stock price forecast is $19.13, which is an increase of 600.73% from the latest price.

Price Target

$19.13

(600.73% upside)

Analyst Consensus: Buy